# Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

> **NCT01386528** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 13 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia B

## Interventions

- **DRUG:** nonacog beta pegol

## Key facts

- **NCT ID:** NCT01386528
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-07
- **Primary completion:** 2013-12-01
- **Final completion:** 2013-12-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01386528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01386528, "Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01386528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*